Gamida Cell Announces Pricing of $65 Million Public Offering of Ordinary Shares
December 17 2020 - 9:43AM
Business Wire
Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy
company committed to cures for blood cancers and serious
hematologic diseases, today announced the pricing of a follow-on
public offering of 8,125,000 ordinary shares at a public offering
price of $8.00 per share for aggregate gross proceeds of $65.0
million, before deducting underwriting discounts and commissions
and estimated offering expenses. In addition, Gamida Cell has
granted the underwriters a 30-day option to purchase up to an
additional 1,218,750 ordinary shares at the public offering price,
less the underwriting discounts and commissions. The offering is
expected to close on or about December 21, 2020, subject to
satisfaction of customary closing conditions.
Gamida Cell intends to use the net proceeds from this offering,
together with its existing cash and cash equivalents, available for
sale and short-term deposits: to fund (i) the preparation of a
potential commercial launch of omidubicel; (ii) the continued
clinical development of its product candidates, including GDA-201;
(iii) the expansion of its commercial manufacturing capabilities;
and (iv) general corporate purposes, including general and
administrative expenses and working capital.
Piper Sandler & Co., Evercore Group L.L.C. and JMP
Securities LLC are acting as joint book-running managers for this
offering.
A registration statement relating to these securities has been
filed with the Securities and Exchange Commission on Form F-3 (File
No. 333-234701) and declared effective on November 27, 2019. This
offering will be made only by means of a prospectus supplement.
Copies of the final prospectus supplement and the accompanying
prospectus related to this offering may be obtained, when
available, from: Piper Sandler & Co., 800 Nicollet Mall,
J12S03, Minneapolis, Minnesota 55402, Attention: Prospectus
Department, by telephone at (800) 747-3924 or by email at
prospectus@psc.com; Evercore Group L.L.C., 55 East 52nd Street, New
York, New York 10055, Attention: Equity Capital Markets, by
telephone: (888) 474-0200, or by email:
ecm.prospectus@evercore.com; or JMP Securities LLC, 600 Montgomery
Street, 10th Floor, San Francisco, CA 94111, Attention: Prospectus
Department, by calling (415) 835-8985 or by email at
syndicate@jmpsecurities.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities, in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Gamida Cell
Gamida Cell is an advanced cell therapy company committed to
cures for blood cancers and serious blood diseases. We harness our
cell expansion platform to create therapies with the potential to
redefine standards of care in areas of serious medical need.
Forward Looking Statements
This press release contains forward-looking statements as that
term is defined in the Private Securities Litigation Reform Act of
1995, including with respect to the use of proceeds and timing of
the closing of the public offering. These forward-looking
statements are subject to a number of risks, uncertainties and
assumptions, including those that are described in the Risk Factors
sections of the preliminary prospectus supplement for such offering
filed with the SEC on December 17, 2020, and the documents
incorporated by reference therein, including without limitation the
Company’s Annual Report on Form 20-F filed with the SEC on February
26, 2020, the accompanying prospectus and other filings that Gamida
Cell makes with the SEC from time to time (which are available at
http://www.sec.gov), which could cause the events and circumstances
discussed in such forward-looking statements not occur on the terms
described or at all. Prospective investors are cautioned not to
place undue reliance on such forward-looking statements, which
speak only as of the date hereof. Gamida Cell undertakes no
obligation to update any such forward-looking statements after the
date hereof, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201217005698/en/
Investor Contact: Stephanie Ascher Stern Investor
Relations, Inc. stephanie.ascher@sternir.com 1-212-362-1200
Media Inquiries: Matthew Corcoran
mcorcoran@tenbridgecommunications.com 1-617-866-7350
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Apr 2023 to Apr 2024